Lakeshore Recycling Systems (LRS) will join with the Lupus Society of Illinois (LSI) to raise money and disease awareness through the 2016 Chicago Illinois Lupus Walk. This year’s walk will take place on Sunday, Sept. 18, at Lincoln Park, from 9:00 a.m. to 1:00 p.m. Participants may choose distances of…
A recently released poll shows widespread public support among residents of San Jose, California, in favor of patient access to medical marijuana delivered to their homes — 63% in favor, in fact — as the City Council prepares to begin considering new regulations for businesses working in this area. Medical marijuana is…
Researchers at the Singapore Immunology Network at A*STAR have found that immune dendritic cells are crucial for the development of kidney disease in systemic lupus erythematosus (SLE). The study, “RNA sensing by conventional dendritic cells is central to the development of lupus nephritis,” was published in the journal…
Researchers found a specific class of adenosine receptors called A2A that works to counter the immune cell hyperactivation observed in systemic lupus erythematosus (SLE) patients, and may be a new target for disease treatment. The study, “A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus…
A recently published clinical study announced by Resolve Therapeutics shows that the levels of blood circulating RNA are connected to disease activity and immune stimulating gene expression in systemic lupus erythematosus (SLE) patients. The finding offers new treatment target for the disease. The study, “Blood-borne RNA correlates with disease activity and…
I’ve been wanting to talk about this subject for a while now, but it’s so complex a topic that I didn’t even know where to start. Hell, I hate ’em and love ’em all in the same instance, but they are a necessary evil in my life. You…
Anthera Pharmaceuticals announced that William Shanahan, MD, has been appointed its chief medical officer, with responsibilities that include advancing a potential treatment for systemic lupus erythematosus (SLE) now in a Phase 3 clinical study. Shanahan, a rheumatologist, brings to the company years of experience in drug development, and will lead the analysis of results…
Idera Pharmaceuticals recently presented pre-clinical data on the mechanisms of action behind its antisense (3GA) technology platform, a gene silencing technology whose potential disease indications include, but are not limited to, lupus nephritis. Idera’s 3GA technology specifically silences disease-causing genes using small molecules called oligonucleotides, which offer an improvement over…
The Lupus Research Alliance welcomed the report, by Aurinia Pharmaceuticals, of positive top-line results in its Phase 2 clinical trial results of voclosporin, an investigational treatment for lupus nephritis (LN). The group, however, is awaiting further analysis of findings, especially those addressing potential safety concerns. Lupus nephritis (LN) is a…
In a recent published article, the president and chief executive officer of Lupus Foundation of America (LFA) Sandra C. Raymond discussed important aspects of lupus mortality. “Over the years, pioneering physicians, using therapies borrowed from other diseases, have painstakingly developed treatment regimens that have helped to reduce mortality associated with…